Check out your Company Bowl for anonymous work chats.
Despite initial signs of recovery at the end of the third quarter, soft customer demand that lasted longer than expected shaped the business development of the life science group Sartorius in the first nine months of 2023. After pandemic-related extraordinary business and inventory buildup by customers had triggered strong additional growth momentum in previous years, the company recorded declines in sales revenue and profitability. “2023 will be a year of normalization for Sartorius as well as for the market as a whole. We expect the business situation to continue to improve slightly in the fourth quarter, especially in the Bioprocess Solutions division, and anticipate profitable growth in 2024 and beyond,” said Sartorius CEO Joachim Kreuzburg. Read press release: https://srtrs.info/89zay
Sartorius has made it once again into Forbes’ List of the World's Best Employers. Forbes magazine, in collaboration with research institute Statista, surveyed 170,000 full- and part-time employees of multinational companies across more than 50 countries to identify the best employers in terms of talent development, remote working options, parental leave benefits, diversity, work-life balance and pride in the product or services the company offers. Read more on the Sartorius blog: https://ow.ly/MYpO50PX9GV
Sartorius has announced its long-term plans to expand its existing site in Ajdovščina, Slovenia, into a campus within the next ten years. The plans were unveiled at the 25th anniversary celebration of BIA Separations, which Sartorius acquired in 2020. During the ceremony, attended by Sartorius Executive Board members Joachim Kreuzburg and René Fáber, a new building was inaugurated at the existing site. According to the new concept, approximately 200 new skilled positions could be created at the future campus. The site is projected to have a total area of around 30,000 square meters and will be a multifunctional complex comprising production, research, and education facilities. The campus will be designed to be sustainable, including a solar power plant and technologies to recycle by-products for heating and water reuse. Read more: https://srtrs.info/w6tj4
Sartorius is expanding its climate strategy and targets to include the long-term goal of fully decarbonizing its business activities by 2045. The company plans to achieve climate neutrality by continuously decarbonizing along the value chain with customers and suppliers and offsetting unavoidable residual emissions in line with the Paris Climate Agreement. An important step in this ambition will be the transition to 100% renewable electricity across the company’s more than 60 sites worldwide by 2030. Furthermore, the Group's medium-term climate targets, which were announced in 2021 and include an average reduction of emissions intensity by 10% per year, are now to be supplemented by science-based climate targets. Sartorius made a corresponding commitment to the Science Based Targets initiative. Read press release: https://srtrs.info/gtuxc
With National Coming Out Day approaching, Inara Mueller, Field Service Engineer in the Greater Philadelphia area, shares her experiences as a transgender woman in the biotech industry as well as insights and tips. "I think what makes terms like transgender and cis a little difficult for some people to understand is the common misconception that gender is just one concept. There are essentially four dimensions to gender: identity, expression, sex, and attraction. The misconception is that your anatomical sex automatically corresponds to your identity and expression. This is the case for cis people. But it's just not the case for everyone." Read the full interview and learn more on the Sartorius blog: https://srtrs.info/n011l
From Germany to India, the U.S., and beyond: Sartorius offers experts in their field numerous opportunities to contribute their ideas and realize their ambitions worldwide. With more than 15,000 colleagues around the globe, we work towards our common goal: Better health for more people. Visit www.sartorius.com/careers and find your next position
Looking for a partner at every stage of your journey? Our innovative research tools, automated analytical instruments, biomanufacturing and purification solutions are designed to make drug discovery and production simpler, faster, and more sustainable. But we don't just provide cutting-edge technology. We understand that our partners' development and production needs are unique - and we actively listen, anticipate and act to meet them. We're in this together. We offer leading solutions from drug discovery to production and final shipping. Discover our range of solutions at www.sartorius.com/inthistogether
Sartorius and SPARTA Biodiscovery, a spin-out company from Imperial College London, have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugs. “The SPARTA platform will help customers optimize the design of nanoparticles at an early stage, even before the drug candidates move on to the clinic. We have teamed up to bring additional product commercialization and application expertise to the table to facilitate a swift transitioning from prototype to launch,” said Prof. Dr. Oscar-Werner Reif, Head of Corporate Research and CTO at Sartorius. Read press release: https://srtrs.info/dgpcj
Bringing personalized cell therapies to more people? Whether it is cancer, genetic disorders, or autoimmune diseases - there are high hopes for cell and gene therapies. Scientists and engineers explore new frontiers of drug discovery, development, and manufacturing to reveal the full potential of these advanced therapies and make them accessible to more patients. And we are right there with them. Because: We’re in this together. Let’s start working together at www.sartorius.com/inthistogether
This week, we celebrated a symbolic groundbreaking for the new production facility at our site in Freiburg, Germany. Let’s take this occasion to reflect on the beginnings of cytokine production at Sartorius CellGenix. Back in 2002, Fred Simon, a working student at that time, and some colleagues saw the chance to manufacture high-quality cytokines themselves when the available options didn’t meet GMP standards. Based on Fred's DNA, their idea led to the production of the first cytokines at CellGenix. Read on the Sartorius Blog, how Fred’s blood became a game changer, paving the way to becoming a leading player in pre-clinical and GMP cytokine production for the cell and gene therapy market, and how the team is growing with Sartorius: https://srtrs.info/gqtpu
